The urgent need to ensure that the #COVID19 vaccines will be treated in practice as public goods that are guaranteed for all, has been requested by 38 MEPs through a common letter sent to the Heads of the European Institutions – Ursula von der Leyen, Charles Michel and Antonio Costa.
In the letter, which was an initiative by the Vice – President of the European Parliament and Head of SYRIZA – Progressive Alliance delegation, Mr. Dimitris Papadimoulis, the co-signed MEPs point out, among others, that “the EU should overcome the barriers and restrictions arising from patents and intellectual property rights in order to ensure the widespread production and distribution of vaccines in all countries and to all citizens” and request from the European Union Leadership to “take radical measures to avoid delays in peoples’ access to the new vaccines, overcoming any impasse. In this way, public health but also the economy, employment and social cohesion in Europe could be effectively protected”.
Concluding their letter, the MEPs stressed the importance of: “EU’s reputation as the world’s leading humanitarian aid provider by supporting the World Health Organization (WHO) COVAX initiative to provide affordable and accessible vaccines around the world, especially to the poorest and less developed countries”.
You can find the full letter below:
Subject: Imperative need to ensure the mass vaccination against COVID-19 for all
Dear President von der Leyen, Dear President Michel,
Dear Prime Minister Costa,
It has been more than a year since we witnessed the first recorded cases of COVID-19. Since then the virus has caused an unprecedented crisis that has cost millions of lives worldwide and has devastated our societies, our healthcare systems and our economies.
During this period, we have also witnessed an unprecedented collaboration between scientists to develop effective COVID-19 vaccines and treatments. Their contribution has been crucial in accelerating the development of the first vaccines and in the successful conduct of clinical trials. However, now that the results of scientific efforts have started to bear fruit, the stakes are to ensure the timely mass production and availability of safe, effective and affordable vaccines in order to quickly achieve collective immunisation of the population and to radically curb the pandemic.
On 21 December 2020, the European Commission approved the COVID-19 vaccine developed by BioNTech and Pfizer, following the positive recommendation by the European Medicines Agency (EMA), and the first delivery of the vaccine to Member States was carried
out on 26 December 2020. Moreover, on 6 January 2021, the Commission also approved the COVID-19 vaccine developed by Moderna. Unquestionably, these are positive developments.
However, it is still uncertain if the EMA will recommend AstraZeneca vaccine in January, while Sanofi and GSK have announced that their COVID-19 vaccines will not be ready until the end of 2021, the vaccine under development by Johnson & Johnson is not expected before March and the doses ordered from CureVac are not expected until the summer.
In this context, it is imperative to avoid any cases of non-compliance with vaccine delivery schedules and any shortages of available quantities, which could cause significant delays in the vaccination of healthcare workers and vulnerable groups as well as of the general population.
These circumstances underline the need to rethink our ways and redesign our course of action. Complementing the significant amounts of funds that have been channelled by the EU for the development and production of the vaccines, the EU leadership should now take radical measures to avoid delays in peoples’ access to the new vaccines, overcoming any impasse. In this way, public health but also the economy, employment and social cohesion in Europe could be effectively protected.
It is time for COVID-19 vaccines to be treated in practice as public goods that are guaranteed for all. To this end, the EU should overcome the barriers and restrictions arising from patents and intellectual property rights in order to ensure the widespread production and distribution of vaccines in all countries and to all citizens.
Last but not least, the EU should live up to its reputation as the world’s leading humanitarian aid provider by supporting the World Health Organization (WHO) COVAX initiative to provide affordable and accessible vaccines around the world, especially to the poorest and less developed countries. As the WHO has pointed out, no one will ever be truly safe until everyone is safe.
Yours sincerely,
Dimitrios PAPADIMOULIS (The Left), Rasmus ANDRESEN (Verts/ALE), Konstantinos ARVANITIS (The Left), Pernando BARRENA ARZA (The Left), Manuel BOMPARD (The Left), Marc BOTENGA (The Left), Reinhard Hans BÜTIKOFER (Verts/ALE), Leila CHAIBI (The Left), Ignazio CORRAO (Verts/ALE), Clare DALY (The Left), Özlem DEMIREL (The Left), Cornelia ERNST (The Left), Daniel FREUND (Verts/ALE), Giorgos GEORGIOU (The Left), Alexis GEORGOULIS (The Left), Francisco GUERREIRO (Verts/ALE), José GUSMÃO (The Left), Henrike HAHN (Verts/ALE), Petros KOKKALIS (The Left), Kateřina KONEČNÁ (The Left), Stelios KOULOGLOU (The Left), Elena KOUNTOURA (The Left), Aurore LALUCQ (S&D), Erik MARQUARDT (Verts/ALE), Marisa MATIAS (The Left), Emmanuel MAUREL (The Left), Tilly METZ (Verts/ALE), Silvia MODIG (The Left), Hannah NEUMANN (Verts/ALE), Jutta PAULUS (Verts/ALE), Maria Eugenia RODRÍGUEZ PALOP (The Left), Martin SCHIRDEWAN (The Left),
Helmut SCHOLZ (The Left), Ernest URTASUN (Verts/ALE), Monika VANA (Verts/ALE), Idoia VILLANUEVA RUIZ (The Left), Nikolaj VILLUMSEN (The Left), Mick WALLACE (The Left)
MEPs letter on Covid-19 vaccines
Χρησιμοποιούμε cookies για να σας προσφέρουμε την καλύτερη δυνατή εμπειρία πλοήγησης και να αναλύουμε την επισκεψιμότητα της ιστοσελίδας μας. Με την παραμονή σας στην ιστοσελίδα, αποδέχεστε τη χρήση cookies όπως αυτή περιγράφεται στην Πολιτική Cookies ΟΚ
